CRVO
CervoMed Inc
$
7.050
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
7.4582
Open
7.140
VWAP
7.23
Vol
60.03K
Mkt Cap
65.23M
Low
7.0071
Amount
434.11K
EV/EBITDA(TTM)
--
Total Shares
8.25M
EV
27.82M
EV/OCF(TTM)
--
P/S(TTM)
7.95
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
0.00
-100%
-0.515
-8.04%
1.30M
-39.87%
-0.556
-30.54%
1.42M
-26.97%
-0.657
+19.48%
Estimates Revision
The market is revising Upward the revenue expectations for CervoMed Inc. (CRVO) for FY2025, with the revenue forecasts being adjusted by 20.76% over the past three months. During the same period, the stock price has changed by -24.44%.
Revenue Estimates for FY2025
Revise Upward
+20.76%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+18.04%
In Past 3 Month
Stock Price
Go Down
-24.44%
In Past 3 Month
5 Analyst Rating
Wall Street analysts forecast CRVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRVO is 21.80 USD with a low forecast of 11.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 7.050
Low
11.00
Averages
21.80
High
31.00
Current: 7.050
Low
11.00
Averages
21.80
High
31.00
Roth Capital
Buy
upgrade
$16 -> $20
2025-10-17
Reason
Roth Capital
Price Target
$16 -> $20
2025-10-17
upgrade
Buy
Reason
Roth Capital raised the firm's price target on CervoMed to $20 from $16 and keeps a Buy rating on the shares. Following a re-analysis of the Phase 2b results, Roth is "convinced" that CervoMed's neflamapimod has the potential to become a new therapy for dementia with Lewy bodies. The firm increased the drug's probability of success to 50% from 40%, prompting the higher price target.
H.C. Wainwright
H.C. Wainwright
Neutral
maintain
$11
2025-09-08
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$11
2025-09-08
maintain
Neutral
Reason
H.C. Wainwright set a price target of $11 for CervoMed shares while keeping a Neutral rating on the name. The regulatory outlook for neflamapimod should be clarified in the near-term, the analyst tells investors in a research note. The firm says CervoMed is actively preparing for discussions with the FDA, which management expects to take place during Q4.
D. Boral Capital
Jason Kolbert
Buy
upgrade
$15 -> $31
2025-08-18
Reason
D. Boral Capital
Jason Kolbert
Price Target
$15 -> $31
2025-08-18
upgrade
Buy
Reason
D. Boral Capital analyst Jason Kolbert raised the firm's price target on CervoMed to $31 from $15 and keeps a Buy rating on the shares. The firm increased its probability of clinical success for neflamapimod in dementia with Lewy bodies to 30% from 15% based on recently presented data. The recent results "materially strengthen" the late-stage outlook for the program and address uncertainties, the analyst tells investors in a research note. D. Boral points out that the underdosed patients performed like placebo, while fully dosed patients drove the efficacy signal.
Roth Capital
Boobalan Pachaiyappan
Buy
downgrade
$20 -> $16
2025-08-12
Reason
Roth Capital
Boobalan Pachaiyappan
Price Target
$20 -> $16
2025-08-12
downgrade
Buy
Reason
Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on CervoMed to $16 from $20 and keeps a Buy rating on the shares after its Q2 results. Following positive Week 32 Phase 2b OLE data, CervoMed is slated to meet with the FDA in Q4 to discuss the results generated to date and obtain guidance on its Phase 3 study preparations, the analyst tells investors in a research note. Roth has also updated its model that assumes $78M in equity financing, the firm added.
Canaccord
Buy
maintain
$21 -> $27
2025-07-29
Reason
Canaccord
Price Target
$21 -> $27
2025-07-29
maintain
Buy
Reason
Canaccord raised the firm's price target on CervoMed to $27 from $21 and keeps a Buy rating on the shares. The firm raised its target following the release of impressive 32-week Phase 2b datafor neflamapimod in dementia with Lewy bodies (DLB). When viewed in the light of the unmet need in DLB, which remains very high, they believe regulatory alignment on a pivotal program design could drive upside from current levels.
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$10
2025-03-26
Reason
D. Boral Capital
Jason Kolbert
Price Target
$10
2025-03-26
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for CervoMed Inc (CRVO.O) is -3.08, compared to its 5-year average forward P/E of -5.88. For a more detailed relative valuation and DCF analysis to assess CervoMed Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-5.88
Current PE
-3.08
Overvalued PE
-2.30
Undervalued PE
-9.46
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-3.36
Current EV/EBITDA
-0.74
Overvalued EV/EBITDA
-0.25
Undervalued EV/EBITDA
-6.47
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
15.10
Current PS
7.05
Overvalued PS
23.66
Undervalued PS
6.54
Financials
Annual
Quarterly
FY2025Q2
YoY :
-46.56%
1.76M
Total Revenue
FY2025Q2
YoY :
+120.90%
-6.62M
Operating Profit
FY2025Q2
YoY :
+170.12%
-6.26M
Net Income after Tax
FY2025Q2
YoY :
+159.26%
-0.70
EPS - Diluted
FY2025Q2
YoY :
+195.90%
-6.51M
Free Cash Flow
FY2025Q2
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q2
-299.79
FCF Margin - %
FY2025Q2
YoY :
+405.47%
-356.05
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CRVO News & Events
Events Timeline
2025-10-28 (ET)
2025-10-28
08:26:01
CervoMed names Quigley to its board of directors
2025-10-08 (ET)
2025-10-08
07:03:27
CervoMed Reveals New Findings from Phase 2b Trial of RewinD-LB
2025-10-07 (ET)
2025-10-07
08:34:36
CervoMed Names Matthew Winton as Chief Commercial and Business Officer
Sign Up For More Events
Sign Up For More Events
News
1.0
10-20GlobenewswireJoin the Live Stream of Day 1 at the Emerging Growth Conference 87 on October 22. Register Now!
1.0
10-20NewsfilterCervoMed to Showcase at the Emerging Growth Conference
9.0
10-08NewsfilterCervoMed Reveals New Phase 2b Trial Data Highlighting Neflamapimod's Promise for Treating Dementia with Lewy Bodies
Sign Up For More News
People Also Watch
FEBO
Fenbo Holdings Ltd
0.780
USD
-4.88%
SAIH
SAIHEAT Ltd
7.850
USD
-0.44%
PLAG
Planet Green Holdings Corp
1.830
USD
-12.02%
ACXP
Acurx Pharmaceuticals Inc
5.020
USD
-1.57%
LIQT
LiqTech International Inc
2.350
USD
+3.07%
SYBX
Synlogic Inc
1.690
USD
-1.17%
CLIK
Click Holdings Limited
7.060
USD
-1.40%
JDZG
JIADE Ltd
2.040
USD
+7.65%
NNVC
NanoViricides Inc (Pre-Reincorporation)
1.660
USD
-2.35%
IZM
ICZOOM Group Inc
1.800
USD
-6.74%
FAQ
What is CervoMed Inc (CRVO) stock price today?
The current price of CRVO is 7.05 USD — it has decreased -0.84 % in the last trading day.
What is CervoMed Inc (CRVO)'s business?
What is the price predicton of CRVO Stock?
What is CervoMed Inc (CRVO)'s revenue for the last quarter?
What is CervoMed Inc (CRVO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for CervoMed Inc (CRVO)'s fundamentals?
How many employees does CervoMed Inc (CRVO). have?